title: Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis.
abstract: Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372-24,199). This cost was partially offset, with savings in direct cost estimated to range from USD -1135 (95% CI -2,050 to -328) to USD -4,422 (95% CI -6,552 to -2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD -774 (95% CI -2,019-535) to USD -1,875 (95% CI -3,650 to -188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.
authors.affiliation: Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, SE-17177 Stockholm, Sweden. axel.svedbom@ki.se.
authors.forename: Axel
authors.initials: A
authors.lastname: Svedbom
authors.forename: Johan
authors.initials: J
authors.lastname: Dahlén
authors.forename: Carla
authors.initials: C
authors.lastname: Mamolo
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Cappelleri
authors.forename: Lotus
authors.initials: L
authors.lastname: Mallbris
authors.forename: Ingemar F
authors.initials: IF
authors.lastname: Petersson
authors.forename: Mona
authors.initials: M
authors.lastname: Ståhle
mesh_terms: D001688:Biological Products / Q000191:economics*; D015897:Comorbidity; D017281:Cost of Illness; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics*; D012042:Registries; D012720:Severity of Illness Index; D013548:Sweden
chemical_list: D001688:Biological Products